Association for Behavior Analysis International

The Association for Behavior Analysis International® (ABAI) is a nonprofit membership organization with the mission to contribute to the well-being of society by developing, enhancing, and supporting the growth and vitality of the science of behavior analysis through research, education, and practice.

Search

50th Annual Convention; Philadelphia, PA; 2024

Event Details


Previous Page

 

Paper Session #464
The Evaluation of a “Critical Period” in Contingency Management for Cocaine Use Disorder
Monday, May 27, 2024
12:00 PM–12:25 PM
Convention Center, 100 Level, 102 AB
Area: BPN
Instruction Level: Intermediate
Chair: Sean Regnier (University of Kentucky)
 
The Evaluation of a “Critical Period” in Contingency Management for Cocaine Use Disorder
Domain: Applied Research
SEAN REGNIER (University of Kentucky), Thomas Shellenberg (University of Kentucky), Mikhail Koffarnus (University of Kentucky College of Medicine), David Cox (University of Kentucky), Joshua Anthony Lile (University of Kentucky), Craig Roy Rush (University of Kentucky), William Stoops (University of Kentucky)
 
Abstract: Decreasing drug use during the early stages of treatment has predicted later success in several substance use interventions. However, this “critical period” has not been reported in Contingency Management (CM) trials. This analysis determined if, after accounting for incentive condition, abstinence in a CM trial for people with Cocaine Use Disorder (CUD) could be predicted by cocaine use during a first-week critical period. Eighty-seven participants with CUD were randomized to receive contingent high or low value incentives for cocaine abstinence or were in a non-contingent control group. Generalized estimating equations (GEE) were used to analyze urine test results over 36 clinic visits during intervention. To assess for a critical period, the first three visits were included in the GEE as a covariate for remaining urine test results. As expected, significantly reduced cocaine use was observed in the High Value group relative to the control group (OR = 2.80; p = 0.01). Additionally, participants who provided more negative samples during the critical period were significantly more likely to produce negative urine samples during the remainder of the trial. These results 1) reinforce the effectiveness of CM for CUD and 2) demonstrate the existence of a critical period in CM.
 
 

BACK TO THE TOP

 

Back to Top
ValidatorError
  
Modifed by Eddie Soh
DONATE
{"isActive":false}